Mei Ri Jing Ji Xin Wen·2025-12-28 23:12Group 1 - ST HuLuWa and its chairman Liu Jingping are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1] - The company claims that its production and operational activities are currently normal and orderly [1] Group 2 - BaiLi TianHeng plans to apply for the registration and issuance of debt financing instruments to optimize its debt structure, with a proposed issuance scale not exceeding 10 billion RMB [2] - The company asserts that this initiative will promote high-quality, stable, and sustainable development, benefiting all shareholders without harming minority shareholders [2] Group 3 - PaiLin Bio's controlling shareholder has signed a supplementary agreement for share transfer, extending the final deadline for the transaction to June 30, 2026, due to ongoing state-owned enterprise and antitrust reviews [3] - The share transfer is subject to compliance confirmation from the Shenzhen Stock Exchange and other regulatory approvals [3] Group 4 - JinCheng Pharmaceutical's subsidiary is required to pay approximately 21.6 million RMB in back taxes and penalties for the years 2017 and 2018, which have now been settled [4] - The company plans to seek compensation from previous equity transfer parties, with a potential impact of approximately -9.93 million RMB on the net profit attributable to shareholders for the current period [4] Group 5 - HengRui Pharmaceutical has signed an exclusive licensing agreement with HanSen Pharmaceutical for the SHR6508 project, allowing HanSen to commercialize the product [5] - This agreement enables HengRui to focus resources on priority treatment areas and leverage commercial services to expedite market entry [5]